Evidence map›Paper›PMID 41386560›Full record

ReviewRespiratory medicine2026

Predictors of respiratory decline in neuromuscular disorders.

Lynn Basbous, Sara El Abiad, Debolina D Biswas, Yochebed Woldeyohannes, Amr ElMahalawy, Mostafa M Abdelbarr, Wissam Mansour, Marán Y Hernández Rodríguez, Natalie Katz, Mai K ElMallah

Abstract readReview
In one paragraph

Review in Respiratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lynn BasbousDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Sara El AbiadDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Debolina D BiswasDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Yochebed WoldeyohannesDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Amr ElMahalawyDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Mostafa M AbdelbarrDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Wissam MansourDivision of Pulmonary, Allergy and Sleep Medicine, Department of Medicine, School of Medicine, Duke University, Durham, NC, USA.
Marán Y Hernández RodríguezDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Natalie KatzDivision of Neurology, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA.
Mai K ElMallahDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, School of Medicine, Duke University, Durham, NC, USA. Electronic address: mai.elmallah@duke.edu.

Funding

Optimizing Gene Therapy for Respiratory Insufficiency in Duchenne Muscular DystrophyR01HL171282 · NHLBI · DUKE UNIVERSITY · PI Mai ElMallah · 2024 to 2026
$1.9M
Alveolar injury and repair in Pompe DiseaseR01HL177642 · NHLBI · DUKE UNIVERSITY · PI Mai ElMallah, Aleksandra Tata · 2025 to 2026
$1.5M
NHLBI NIH HHS R01 HL171282NHLBI NIH HHS R01 HL177642
6 · The paper itself

Abstract

Neuromuscular diseases (NMDs) constitute a heterogeneous group of genetic and acquired disorders that lead to progressive muscle weakness. When the respiratory muscles are involved, impaired ventilation and ineffective airway clearance become a major source of morbidity and mortality. Respiratory insufficiency is one of the major contributors to mortality in NMDs, with considerable variation in onset and rate of progression across different diseases. Patients with NMD have progressive weakness of the diaphragm and accessory respiratory muscles. This weakness leads to reduced chest wall compliance and restrictive lung disease. In some NMDs, bulbar dysfunction results in impaired airway clearance and aspiration pneumonia. Despite advances in care, predicting the onset of respiratory decline in NMDs remains a major clinical challenge. This narrative review aims to synthesize the current evidence on predictors of respiratory decline in NMDs. We comprehensively evaluate a broad spectrum of clinical, physiological, cellular, imaging, genetic, and digital markers that have emerged as predictors for respiratory decline in NMDs. These include age-related trends, pulmonary function tests, strength assessments, advanced imaging modalities, blood and serum biomarkers, genetic variants, scoring systems, and emerging smartphone based tools. By highlighting these factors, we underscore their potential to improve the early detection of respiratory impairment and guide timely interventions.

Indexed as

Neuromuscular DiseasesRespiratory InsufficiencyBiomarkersDisease ProgressionHumansMuscle WeaknessRespiratory Function TestsRespiratory MusclesBiomarkersMarkersNeuromuscular diseasesRespiratory complicationsRespiratory decline

Identifiers

PMID41386560
PMCPMC13648322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.